Five Additional EU Member States Able to Perform GMP Inspections Equivalent to US Level
Five additional European Union member states have been confirmed by the US Food and Drug Administration (FDA) as capable of performing good manufacturing practice inspections at a level equivalent to that of the United Sates
Five additional European Union member states have been confirmed by the US Food and Drug Administration (FDA) as capable of performing good manufacturing practice inspections at a level equivalent to that of the United States, it was revealed in Nov. 29, 2018 news story from the European Medicines Agency (EMA).
On Nov. 16, 2018, Belgium, Denmark, Finland, and Latvia, and Nov. 28, 2018, Estonia, were included in the mutual recognition agreement (MRA) currently in place between the European Union and the US. The MRA allows for the mutual recognition of manufacturing site inspections for human medicines that are conducted within the relevant territories. With the latest five additions, the FDA will be able to rely on a total of 20 EU member states for inspection results.
Since Nov. 1, 2017, European member states as well as EMA have been able to rely on GMP inspections carried out by FDA. Furthermore, the plans for all EU member states to be included within the EU-US MRA by July 15, 2019, have been reported as ‘on track’.
Source: EMA
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
